San Diego-based personalized medicine developer Ignyta
has raised $1M in funding, via a capital term loan from Silicon Valley Bank, the company disclosed this morning. The firm--which is focusing on treating rheumatoid arthritis (RA), lupus and other autoimmune diseases, said the new $1M capital term loan facility comes on top of an existing, $500K facility it has with SVB. Financial details of that term loan were not disclosed. Ignyta is venture backed by Colt Ventures, City Hill Ventures, and others.
posted on Thursday, February 28, 2013
> Ignyta Raises $42M From Teva, Buys Oncology Assets
> Ignyta Prices IPO
> Ignyta Gets $10M In Term Loan
> Ignyta Sets Chief Commercial Officer
> Ignyta Hits Public Markets In Reverse Merger